The role of the bladder tumour antigen test in the management of gross haematuria.
BACKGROUND
The bladder tumour antigen (BTA) test has been found to be more sensitive than urine cytology for the detection of recurrent bladder cancer. We chose to evaluate the role of the bladder tumour antigen test in the management of gross haematuria on initial presentation.


METHODS
A prospective analysis over a 3-month period of consecutive cases of gross haematuria was conducted. Routine investigations including intravenous urogram, flexible cystoscopy, urine cytology testing and BTA testing were performed. Results were correlated with the final diagnosis, and also with histology and tumour stage in the cases of malignant outcome.


RESULTS
The prevalence of malignancy in our series was 25.5%. Sensitivity of the BTA test was 67% and specificity 66%. This was compared to cytology which yielded a sensitivity of 66% and specificity of 100%. There were 12 cases of falsely positive results on BTA testing, giving a positive predictive value of 40%. Four cases of falsely negative results were all from superficial tumours.


CONCLUSIONS
In view of its poor sensitivity and positive predictive value, the BTA test has a limited role in the initial management of gross haematuria.
Chong
T W
TW
Department of Urology, Singapore General Hospital, Singapore.
Cheng
C
C
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D017242:Complement Factor H; D003558:Cystoscopy; D005188:False Negative Reactions; D005189:False Positive Reactions; D005260:Female; D006417:Hematuria / Q000175:diagnosis* / Q000209:etiology / Q000652:urine; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D015995:Prevalence; D011446:Prospective Studies; D012680:Sensitivity and Specificity; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000652:urine; D014567:Urography
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; C493495:CFH protein, human; C112999:bladder tumor-associated antigen; D017242:Complement Factor H